need to be demonstrated in randomized trials. Such trials are Is folate a promising agent in the prevention and treatment of currently underway in patients with normal renal function at cardiovascular disease in patients with renal failure? Managehigh risk for cardiovascular disease, and one trial has recently ment of the conventional cardiovascular risk factors is insuffibeen initiated in stable renal transplant recipients. cient to prevent the dramatic increase in atherosclerotic cardiovascular morbidity and mortality in patients with renal failure. pears to be independent of its homocysteine-lowering capacity Folate derivatives feature in a variety of biosynthetic and is possibly related to an improved bioavailability of nitric pathways that are critical for purine and pyrimidine meoxide. However, folate has failed to improve endothelial dystabolism and cell replication [3] . In addition, folate plays function in uremic patients. In the ESRD population, multiple an essential role in homocysteine metabolism (Fig. 1) metabolic and hemodynamic abnormalities adversely affect enand is well-known as the primary treatment modality for dothelial function. In addition, irreversible structural vascular disease already may be present. Folate should, therefore, probhyperhomocysteinemia. Hyperhomocysteinemia is prevably be an integral part of an "endothelial protective regimen," alent in more than 85% of patients with end-stage renal consisting of lipid-lowering agents, antihypertensives and antidisease (ESRD). In the past decade, homocysteine has oxidant vitamins and started very early in patients with renal been widely recognized as an independent predictor of failure. Before large-scale folate administration can be recomcardiovascular disease, not only in the general populamended, effects on hard endpoints of cardiovascular disease tion, but also in renal failure patients. Even a total plasma homocysteine (tHcy) level in the top fifth of the distribution curve is significantly correlated with an increased
need to be demonstrated in randomized trials. Such trials are Is folate a promising agent in the prevention and treatment of currently underway in patients with normal renal function at cardiovascular disease in patients with renal failure? Managehigh risk for cardiovascular disease, and one trial has recently ment of the conventional cardiovascular risk factors is insuffibeen initiated in stable renal transplant recipients. cient to prevent the dramatic increase in atherosclerotic cardiovascular morbidity and mortality in patients with renal failure. Folate recently received attention as a potential alternative treatment option to decrease the excess cardiovascular risk in the Atherothrombotic cardiovascular disease remains the uremic population. Folate administration is the principal treatleading cause of morbidity and mortality in patients with ment modality for hyperhomocysteinemia. Hyperhomocysteinrenal failure, regardless of whether they are in the preteremia is prevalent in more than 85% of patients with end-stage minal stage, on maintenance dialysis or have received a renal disease (ESRD) and is independently associated with inkidney transplant [1] . Despite the high prevalence of creased odds for atherosclerotic cardiovascular disease. Several attempts have been made to normalize homocysteine levels in established cardiovascular risk factors in renal failure uremic patients with folate-based vitamin regimens. Although patients, the predictive value of these risk factors for supraphysiologic doses of folic acid afford greater reductions in cardiovascular outcome is not as strong as in the general homocysteine levels than standard doses, the response to treatpopulation. Management of diabetes, hypertension or ment is generally only partial and the large majority of ESRD dyslipidemia is often inadequate and appears insufficient patients have residual hyperhomocysteinemia. Several defects to prevent the excess cardiovascular incidents in patients (PG) that are deconjugated in the intestinal wall to monoglutamates (MG). These compounds are reduced to dihydrofolate (DHF) and subsequently to tetrahydrofolate (THF). THF is converted to 5,10-methylenetetrahydrofolate (5,10-MeTHF), which is irreversibly reduced to 5-methyltetrahydrofolate (5-MTHF) by the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR). 5,10-MeTHF and 10-formyltetrahydrofolate (folinic acid, 10-CHO THF) are used in pyrimidine and purine synthesis, respectively. 5-MTHF plays a central role in homocysteine metabolism. Methionine is converted to S-adenosyl methionine (SAM) and then to S-adenosyl homocysteine (SAH), which is hydrolyzed to homocysteine and adenosine. Homocysteine is either remethylated back to methionine or degraded in the transsulfuration pathway. Cystathionine ␤ synthase (C␤S) is the main enzyme of the transsulfuration pathway and requires vitamin B 6 as a cofactor. Methionine synthase catalyzes remethylation of homocysteine and uses 5-MTHF as cosubstrate and vitamin B 12 as a cofactor. An alternative remethylation route uses betaine as cosubstrate. hyperhomocysteinemia in renal failure patients proves beneficial action of folate on endothelial cell metabolism, independent of its homocysteine-lowering potential, is quite refractory to standard folate-containing B-vitamin supplementation.
discussed. Finally, the evidence (or the lack of evidence) for an effect of folate supplementation on hard endpoints The present communication addresses the evidence for a potentially disturbed folate metabolism in uremia of cardiovascular disease is addressed. that may be responsible for the apparent inefficiency of FOLATE METABOLISM IN RENAL FAILURE folate to normalize homocysteine status in patients with renal failure. In addition, the extant intervention studies
Patients with renal failure, and in particular those on with folate in this patient population are reviewed, focusdialysis, are at risk for deficiencies of the water-soluble ing on different endpoints. First, the effects of different vitamins, as a result of restricted intake, impaired absorpfolate regimens on tHcy levels are evaluated in predialtion, uremia-induced alterations in metabolism and activysis patients, patients on maintenance dialysis and renal ity, losses during hemo-or peritoneal dialysis and treattransplant recipients, in order to define the optimal dose, ment with erythropoietin [5] [6] [7] [8] . Whereas folate and vitamin B 12 deficiency may be somewhat less common, folate species and combination with other B vitamins that achieves the maximal tHcy-lowering effect. Second, vitamin B 6 deficiency occurs in the large majority of unsupplemented patients on dialysis. Therefore, a vitastudies examining the influence of folate on endothelial dysfunction as an intermediary endpoint for cardiovascumin supplement including vitamin B 6 10 mg/day, vitamin B 12 12 g/day and folic acid 1 mg/day has been recomlar disease are reviewed. More in particular, the potential mended to optimize vitamin status in these patients [9] .
FOLATE AND PLASMA HOMOCYSTEINE LEVELS IN RENAL FAILURE Nevertheless, an inverse correlation between serum and/or erythrocyte folate and tHcy levels has been reported Results of homocysteine-lowering intervention trials even in subjects with normal vitamin status [10] [11] [12] [13] [14] [15] [16] [17] , al-A large number of studies have attempted to normalthough other studies failed to confirm these findings ize tHcy levels in renal failure patients with pharmaco- [18] [19] [20] .
logical folate supplementation ( Table 1) . The rationale Diverse defects in folate metabolism have been dembehind this maneuver is that administration of supraonstrated in experimental and clinical uremia. The intesphysiologic doses of folate enhances the activity of the tinal absorption of 5-methyltetrahydrofolate (5-MTHF) homocysteine remethylation pathway, since folate serves was lower in uremic rats than in control rats, a difference as the cosubstrate in this pathway, thereby consuming that could be attributed to the uremic environment the excess homocysteine. In addition, as outlined above, rather than to an acquired intrinsic defect of the enteroit was assumed that defects in folate metabolism in urecytes [21] . The activity of folate conjugase, an enzyme mia required the administration of high doses of folate. that splits polyglutamate forms of folate into monoglutaAs initial studies with pharmacological folate supplemates and is believed to play a vital role in the absorption mentation were rather disappointing, it was thought that and metabolism of folates, was low in predialysis blood even higher doses were required. Consequently, much samples [22] . The activity was restored to normal after effort has been spent determining the optimal dose, foa hemodialysis session, suggesting the presence of an late species and combination with other B vitamins that inhibitor of the enzyme in uremic plasma [ for folate is 0.4 mg/g) [36] , supraphysiologic doses of folic Taken together, these observations gave rise to the specacid afford significantly greater reductions in tHcy levels. ulation that renal failure is characterized by relative folate Generally, a mean tHcy reduction of about 30% is obdeficiency. Uremic patients may not reach adequate intained, with exceptions reporting a decrease of 60 to 70% tracellular levels of 5-MTHF (the biologically active form [25, 30] . Several studies found close correlations between of folate), even though their total serum folate levels, pretreatment tHcy and the response to therapy [19, 20, as measured by standard assays that do not distinguish 27, 30, 35] . In other words, patients who manifest the between the different folate species, may be normal [25] .
highest tHcy concentrations derive the largest benefit from Therefore, it was proposed that supraphysiologic doses treatment. However, even after treatment, most patients of folic acid are required to normalize homocysteine levels with ESRD have residual hyperhomocysteinemia and only in this patient population. In addition, some authors a limited number of subjects achieve normal levels. It thought it desirable to administer the active form of should be noted that many of these studies used 14 to 16 folate intravenously, in order to circumvent or override mol/L as the upper limit of normal for tHcy, whereas it the defects in folate absorption, glutamation and transhas been demonstrated that levels of 12 to 14 mol/L membrane transport [25] . The issue was recently clarified are already associated with an increased cardiovascular by the finding of normal 5-MTHF fractions and glutarisk [4] . When the currently accepted upper limit of normate chain length in serum and erythrocytes of hemodimal (12 mol/L) is used, virtually none of the patients alysis patients [9] . After oral administration of either with ESRD obtained normal post-treatment tHcy levels. 5-MTHF or folic acid, a substantial increase in 5-MTHF Folate-containing regimens were generally more successwas noted, which was similar in both treatment groups ful in predialysis patients [32] [33] [34] [35] . In a non-controlled [9] . This clinical study thus failed to find any evidence study, 69% of the patients obtained tHcy levels below of defective folate metabolism in uremia. It should be 14 mol/L [33] and 20% fell below 12 mol/L in a rannoted, however, that the erythrocyte contents and distridomized trial [32] . Similarly, renal transplant recipients bution of folate species may not be representative of generally respond well to folate supplementation [36] [37] [38] [39] .
In one study, 65% of renal transplant recipients achieved those of metabolically active folate-dependent tissues. tHcy levels below 12 mol/L with high-dose multivitamin to homocysteine-lowering treatment appears desirable. Betaine did not affect tHcy levels in ESRD patients treatment [36] .
Whereas it is accepted that supraphysiologic folate [16, 29, 41] and therefore should not be included in the homocysteine-lowering regimens. doses are required for the treatment of hyperhomocysteinemia in subjects with renal failure, the exact dose An inverse correlation between tHcy levels and the duration of folate administration has been reported, and that has the optimal homocysteine-lowering capacity has been the subject of continued debate. Whereas two ranthe authors suggested that some patients may require longer periods of treatment to achieve normalization of domized trials in ESRD patients showed that 15 mg folic acid conferred an additional 15 to 25% reduction in tHcy their tHcy [25] . These findings were not supported by other studies where intermediary samples showed that as compared to 1 mg folic acid [9, 31] , several other studies found no benefit of very high folate doses. Doses the effect of folate administration was of rapid onset and sustained [16, 29, 18 , 27]. up to 60 mg/day were not superior in lowering tHcy concentrations than a dose of 15 mg/day [27]. Post-treatIn light of these collective data, the optimal homocysteine-lowering regimen in patients with renal failure apment tHcy was similar in dialysis patients given either 1 or 5 mg/day folic acid [16, 29] and a switch to 15 mg/day pears to be a daily oral supplement of 1 to 5 mg folic acid, combined with 6 to 12 g vitamin B 12 and 10 to 50 was not associated with a further decrease [16] . These findings are in line with a recent study examining the g vitamin B 6 . There is no evidence that intravenous administration is superior to oral administration. Only effects of consecutive increments of the dose of folic acid in hemodialysis patients [19] . The maximal homocysin non-compliant patients, as judged from a failure to increase their vitamin levels, would systemic administrateine-lowering response to folic acid was already obtained at an oral dose of 15 mg/week. Interestingly, erythtion be the preferred way. Such a treatment regimen will normalize tHcy in many renal transplant recipients and rocyte folate levels approached saturation at this dose, whereas serum folate levels continued to rise linearly subjects with preterminal renal failure, but the large majority of patients with ESRD will have substantial residalong with the folate dose [19] . In accordance, an equivalent rise in erythrocyte and serum folate levels was obual hyperhomocysteinemia. Further increasing the dose of folic acid does not afford a greater reduction of tHcy served with doses up to 15 mg/week [13], whereas serum folate levels increased in excess of erythrocyte levels in this population and is therefore not recommended. after a dose of 10 mg/day [20] . Restricted intracellular Can folate normalize tHcy in patients with excess thus appears to limit the efficiency of folate. After renal failure? treatment with folate supplements, the correlation between serum folate and tHcy is lost [13, 40] . Taken toWhereas a comprehensive discussion of all reports addressing the etiology of hyperhomocysteinemia in regether, these data suggest that there is an upper limit in folate status above which no further enhancement of the nal failure is beyond the scope and space limitations of this article, a short review may be required to address remethylation pathway and reduction in tHcy levels can be achieved. The optimal dose of folic acid in renal the cause of the folate resistance in ESRD. Any form of hyperhomocysteinemia is a steady-state condition, failure may be in the range of 1 to 5 mg/day.
Although a dramatic effect of the reduced folate specharacterized by either an increased cellular homocysteine export and/or an impaired elimination of homocyscies folinic acid [25] and 5-MTHF [30] was observed in two non-controlled studies, subsequent randomized teine from the plasma compartment. Folate-and cobalamin-deficient subjects have a normal plasma clearance trials provided no evidence that these folate species afford a greater reduction in tHcy levels than standard of homocysteine before or after vitamin supplementation, indicating that their hyperhomocysteinemia is refolic acid [9, 26] .
Whereas high-dose vitamin B 6 supplementation had lated to an increased net efflux from tissues to plasma [42] . In contrast, the hyperhomocysteinemia in patients no independent effect on fasting tHcy in several noncontrolled studies [17, 34, 39] , a randomized trial found with renal failure is due to a marked reduction of the homocysteine clearance from plasma [43] . Whether this a significant reduction of post-methionine tHcy with vitamin B 6 treatment [37] . As a large proportion of uremic reduced clearance results from the loss of normal intrarenal metabolism, the adverse effects of uremic toxins patients additionally have vitamin B 6 deficiency, inclusion of pyridoxine in homocysteine-lowering regimens on extrarenal metabolism, or a combination of these factors remains conjectural [44, 45] . Whatever the cause is recommended. No additional benefit of vitamin B 12 administration was found in a small group of renal transof the impaired plasma clearance, it is not enhanced by folic acid administration [43] , even though folic acid plant recipients [39] . In contrast, vitamin B 12 lowered tHcy with 35% in dialysis patients with low cobalamin lowers tHcy levels. These findings are particularly well suited to explain why the hyperhomocysteinemia in levels [14] . As the presence of a suboptimal vitamin B 12 status in ESRD is not rare, routine addition of vitamin B 12 ESRD cannot be cured solely with folic acid supple-ments. Folic acid enhances the remethylation of homonine load test in healthy volunteers without affecting the rise in plasma tHcy levels [56] . Parallel in vitro studies cysteine in the tissues and, by virtue of this action, lowers the efflux into the plasma compartment, but does not were conducted to provide a rationale for the vasculoprotective effects of folate, independent of homocysteine affect the primary defect in homocysteine metabolism in renal failure, that is, the prolonged plasma elimination.
metabolism. In physiological conditions, endothelial nitric oxide (NO) synthase predominantly produces NO, In patients with mild-to-moderate renal failure, the acceleration of the remethylation pathway in the tissues but under pathological circumstances the production shifts from NO to superoxide, leading to an impaired bioand resulting decreased homocysteine export may be sufficiently large to override the defect in homocysteine availability of NO [57]. 5-MTHF affects the enzyme in a dual manner: it enhances the production of NO and elimination and obtain new steady state levels in the normal range. In the large majority of patients with reduces the generation of superoxide anions [57] . In addition, 5-MTHF has a direct superoxide scavenging activ-ESRD, however, the new steady state levels will remain elevated.
ity, although weaker than vitamin C [57] . It thus appears that folate improves the bioavailability of NO by preThis new level of understanding hopefully sets the stage for the search for alternative therapies that may venting its oxidative degradation. An increased availability of bioactive NO supports the function of the endothenormalize tHcy in ESRD. One potential approach would be to augment the dialysis-related removal of tHcy. In lium and may protect the vasculature against atherogenic influences. a randomized trial controlling for B vitamin intake, no difference in tHcy levels was found in patients dialyzed Although vascular dysfunction in uremia is characterized by increased oxidative stress and an impaired biowith a F8 or a F80 dialyzer [46] . In contrast, patients randomized to a F500S or a Tricea 150G dialyzer had availability of NO [58] , the effects of folate on endothelial dysfunction in patients with renal failure have been significantly lower tHcy levels as compared to subjects treated with a F60 dialyzer, although tHcy remained disappointing (Table 2 ). In spite of a 23% decrease of tHcy, no change of endothelial-derived proteins or markelevated in all groups [47] .
ers of endothelium-dependent vascular reactivity was FOLATE AND ENDOTHELIAL DYSFUNCTION observed in hemodialysis patients treated with oral folic acid [20] . Similarly, neither endothelial markers nor enEndothelial dysfunction has been demonstrated in subjects with preterminal renal failure, in patients on dothelium-dependent vasodilation improved after longterm treatment of hemodialysis patients with folic acid hemodialysis and peritoneal dialysis and in renal transplant recipients, by the presence of impaired endothe- [16] . When patients with antecedent cardiovascular disease and smokers were excluded, a weak trend for imlium-dependent vasodilation or by increased circulating levels of endothelium-derived proteins [29, [48] [49] [50] . The provement of endothelium-dependent vasodilation was found [16] . Even though a sustained reduction of tHcy finding of endothelial dysfunction represents a window of opportunity, as it identifies patients at risk for develwas obtained, folic acid treatment did not improve endothelial function in peritoneal dialysis patients [29] . It oping clinical vascular complications before the advent of structural vascular disease [51] . Improvement of endoshould be noted that the latter two studies did not include a placebo arm. It is therefore unknown whether endothethelial dysfunction is therefore considered a surrogate endpoint for the reduction in cardiovascular morbidity lial function spontaneously deteriorated during the treatment period, thereby masking a potential beneficial efand mortality.
Recently, several studies reported that folate may refect. Finally, a randomized trial found no improvement in endothelium-dependent vasodilation and plasma von store endothelial dysfunction associated with various risk factors ( Table 2 ). The effects appeared to be indepenWillebrand concentration in predialysis patients after folic acid, although treatment was associated with a moddent of the homocysteine-lowering capacity of folate. Both a single intravenous bolus of 5-MTHF [52] and four est decrease in tHcy from 17.7 to 15.1 mol/L [32]. Several explanations for this apparent failure of folate weeks of oral treatment with folic acid [53] completely restored the impaired endothelium-dependent vasodilato improve endothelial function in renal failure patients can be forwarded. First, if one assumes that the endothetion in the forearm circulation of patients with familial hypercholesterolemia. An acute fat load in healthy vollial dysfunction in renal failure patients is related to hyperhomocysteinemia, no efficient therapy was provided unteers was associated with an increased excretion of oxidative end products and a decreased endotheliumby the administration of folate. In all studies, substantial residual hyperhomocysteinemia was present after treatdependent vasodilation, both of which were prevented by oral treatment with folic acid [54] . Systemic adminisment [16, 20, 29, 32] . Since even mild elevations of tHcy are associated with impaired endothelium-dependent vatration of 5-MTHF restored the endothelial dysfunction in the renal microcirculation of diabetic rats [55] . Finally, sodilation [59], a restoration of endothelial dysfunction could hardly be expected. Second, there are a host of folate normalized endothelial function during a methio- planned or underway, examining the effects of folatebased regimens in subjects with normal renal function adequately treated in these studies. In addition, several renal failure-specific factors that are known to adversely and prior vascular disease or at high risk for vascular events [69] . Recently, a large randomized placebo-conaffect endothelial function may be difficult to manage, including oxidative stress caused by repeated hemodialytrolled trial studying the effect of tHcy-lowering therapy on hard cardiovascular end points in 4000 stable renal sis procedures and high circulating levels of uremic toxins that are endogenous inhibitors of NO synthase [49, 60] . transplant recipients has been initiated under the aegis of the National Institute of Diabetes and Digestive and Third, patients with ESRD already may have suffered irreversible structural vascular disease when they were Kidney Diseases. included in these studies. In this respect, radiologic evi-SAFETY OF FOLATE ADMINISTRATION dence of aortic calcifications was present in 70% and small vessel calcifications of the hand were found in 28%
Several authors have performed a systematic assessment of the potential adverse effects of pharmacologic of dialysis patients treated with folate in one study [20] . Therapy may need to be started early in the preterminal folate supplements in uremic patients and found no apparent evidence for toxicity [17, 25, 27 , 31], suggesting stage of renal failure, when patients only have functional alterations of the endothelium without structural lesions.
that high doses of folic acid are well tolerated and safe in this population. The most feared side effect of folic Finally, the currently used parameters to evaluate endothelial function may not be appropriate in renal failure acid is its ability to mask the hematologic manifestations patients. Whereas the presence of impaired endotheof vitamin B 12 deficiency, while the neurological complilium-dependent vasodilation in the coronary circulation cations progress [70] . While an informal survey suggested is predictive for incident cardiovascular events [51] , no that this complication is extremely rare [70] , routine measuch evidence exists for endothelial dysfunction in the surement of vitamin B 12 concentrations and inclusion of brachial artery or forearm circulation. Studies of endovitamin B 12 in the supplements should completely elimithelium-dependent vasodilation therefore need to be nate this risk. It should be kept in mind that high systemic conducted in clinically more relevant vasculatures [61] , doses of folate may reverse the effectiveness of anticonsuch as the coronary circulation. However, the invasive vulsants [70] . Whether folate compromises the therapeunature of angiographic procedures precludes their routic effects of inhibitors of dihydrofolate reductase, intine use for this purpose. It is our task to develop noncluding methotrexate, pyrimethamine, trimethoprim and invasive tests that enable us to diagnose endothelial dystriamterene, is unknown [70] . function early in the target organs of uremia, and to evaluate the validity of these tests as surrogate endpoints CONCLUSION for cardiovascular disease. Flow measurements with posAlthough folate-containing regimens have succeeded itron emission tomography or magnetic resonance imin consistently lowering tHcy levels in renal failure paaging appear to be an attractive tool in this respect [62] .
tients, hyperhomocysteinemia persists in the large majorIn conclusion, folate restores endothelial dysfunction ity of subjects with ESRD, despite supranormal plasma associated with well-defined risk factors, probably through and erythrocyte folate levels. It should be kept in mind an improvement of the bioavailability of NO. However, that even mild hyperhomocysteinemia is associated with studies in patients with renal failure have not provided an increased risk for atherothrombotic cardiovascular evidence for a beneficial effect of folate on endothelial disease. The modest success of the folate-based regimens dysfunction in these patients.
leaves us now poised to explore alternative treatment FOLATE AND CARDIOVASCULAR options, in order to completely normalize tHcy levels in MORBIDITY AND MORTALITY ESRD. A rational approach to the treatment of this residual hyperhomocysteinemia rests heavily on progress Several studies found higher odds ratios for vascular in the knowledge of the pathogenesis of impaired homodisease in subjects with low folate levels [63] [64] [65] [66] [67] . Users cysteine clearance in renal failure. of folate-containing vitamin supplements experience Evidence has emerged for a broad beneficial action substantial protection from vascular disease [4, 68] . Howof folate on endothelial cell metabolism, independent of ever, since the use of vitamin preparations may be associated with other health-conscious behavior, the signifiits role in homocysteine metabolism and possibly acting
